Almujtama Alraida Medical Co. reported a net profit of SAR 11.4 million for 2023, a 40% slump from SAR 19.1 million a year earlier.
| Item | 2022 | 2023 | Change |
|---|---|---|---|
| Revenues | 367.08 | 407.74 | 11.1 % |
| Gross Income | 118.71 | 129.21 | 8.8 % |
| Operating Income | 24.10 | 13.95 | (42.1 %) |
| Net Income | 19.08 | 11.39 | (40.3 %) |
| Average Shares | 9.50 | 9.50 | - |
| EPS (Riyals) | 2.01 | 1.20 | (40.3 %) |
This was ascribed to the expenses pertaining to the company’s share listing on Nomu-Parallel Market, promotion offers to boost retail sales, and lower contract revenue.
Revenues increased by 11% compared with a year before due to strong sales from the company's activities and divisions.
Total shareholders’ equity, no minority interest, stood at SAR 129.78 million by Dec. 31, 2023, compared to SAR 118.59 million a year ago.
|
Historical Data |
|||
|
Period |
Revenue (SAR mln) |
Net profit (SAR mln) |
EPS (SAR /share) |
|
H1 2022 |
171.80 |
6.84 |
0.72 |
|
H2 2022 |
195.28 |
12.24 |
1.29 |
|
H1 2023 |
204.13 |
11.33 |
1.19 |
|
H2 2023 |
203.61 |
0.06 |
0.01 |
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}